Bio-Rad Laboratories, Inc. reported $2.59B of revenue over the trailing twelve months, +1.4% on the year before. 11 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $2.59B (to Q2 2026). Net income: $222M, trailing twelve months to Q2 2026. Free cash flow: $353M, trailing twelve months to Q2 2026. Operating margin: 2.4%, trailing twelve months to Q2 2026.

BIOBio-Rad Laboratories, Inc.

Healthcare

$366.40+29% 1Y

$366.40

$241.7152 weeks$390.31

BIO as reported

Bio-Rad Laboratories, Inc. reported $2.59B of revenue over the trailing twelve months, +1.4% on the year before. 11 reported series are charted on this page, each one as filed.

$2.59B

Revenue, trailing twelve months · to Q2 2026 · +1.4% against the twelve months before

Net income: $222M
Net income · −30% year on year · trailing twelve months to Q2 2026
Free cash flow: $353M
Free cash flow · −4.8% year on year · trailing twelve months to Q2 2026
Operating margin: 2.4%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for BIO, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$2.59B	+1.4%	Q2 2026
Net income	$222M	−30%	Q2 2026
EPS	$7.99	−32%	Q2 2026
Gross margin	52%	n/a	Q2 2026
Operating margin	2.4%	n/a	Q2 2026
Net margin	4.9%	n/a	Q2 2026
ROE	1.4%	n/a	Q2 2026
ROA	1.0%	n/a	Q2 2026
ROIC	1.2%	n/a	Q2 2026
Free cash flow	$353M	−4.8%	Q2 2026
P/E	45.9	n/a	today

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.